GNH USA

Europe — EMA

Kytril (Granisetron)

GNH USA supplies Kytril (Granisetron), a 5‑HT3 receptor antagonist for preventing chemotherapy, radiation and postoperative nausea and vomiting.

Granisetron

Request sourcing

1
Pack/s

What is Granisetron?

Granisetron, the active ingredient in Kytril, is a 5‑HT3 receptor antagonist presented as an injectable solution for intravenous use. It is employed to prevent and treat nausea and vomiting that occur with chemotherapy, radiation therapy, and postoperative recovery in adult patients, including both acute and delayed phases of emesis.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable global logistics for this essential antiemetic.

What is Granisetron used for?

Kytril, a selective 5‑HT3 receptor antagonist, acts on the emetic pathways triggered by chemotherapy, radiation or surgery.

Chemotherapy‑induced nausea and vomiting: prevents and reduces acute and delayed episodes in patients receiving emetogenic chemotherapy. Radiation‑induced nausea and vomiting: controls nausea and vomiting associated with therapeutic radiation. Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures.

What are the side effects of Granisetron?

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Injection‑site pain or erythema - Mild hypotension

Serious or Rare Side Effects: - Cardiac arrhythmia or QT‑interval prolongation - Severe allergic reaction (anaphylaxis) - Serotonin syndrome when combined with other serotonergic agents - Rare cases of severe hypotension or syncope

What precautions apply to Granisetron?

Kytril should be used with caution in patients with pre‑existing cardiac conditions.

Assess cardiac risk: monitor ECG in patients with known QT prolongation. Review concomitant medications: avoid or closely monitor other QT‑prolonging drugs. Use with caution in hepatic impairment: adjust monitoring as needed. Pregnancy and breastfeeding: consider risk‑benefit ratio; limited data are available. Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Granisetron interact with?

Kytril may interact with several drug classes.

Major Interactions (Avoid): - Other QT‑prolonging agents: increased risk of arrhythmia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise granisetron plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce efficacy.

Moderate Interactions (Monitor Closely): - Serotonergic drugs (e.g., SSRIs, triptans): potential serotonin syndrome. - Anticholinergic agents: may worsen constipation. - Certain anesthetics (e.g., propofol): may enhance hypotensive effect.

Frequently asked questions

What is Kytril used for?+
Kytril contains the active ingredient granisetron and is used to prevent nausea and vomiting that can occur after chemotherapy, radiation therapy, or surgical procedures. It is administered intravenously under the direction of a qualified healthcare professional.
How does granisetron work?+
Granisetron works by selectively blocking serotonin 5‑HT3 receptors on peripheral vagal nerves and in the brain’s chemoreceptor trigger zone. This inhibition stops the transmission of emetic signals, reducing both acute and delayed episodes of nausea and vomiting.
What is the usual dose of Kytril?+
The dose of Kytril is determined by the prescribing clinician based on the type of emetogenic stimulus, patient weight, and institutional protocol. Typical regimens involve a single intravenous dose given before chemotherapy, radiation, or surgery, but exact dosing must follow the healthcare provider’s order.
Is Kytril safe during pregnancy or breastfeeding?+
Safety data for granisetron in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.
How do I order Kytril from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.
How does Kytril compare with other antiemetics?+
Compared with other 5‑HT3 antagonists such as ondansetron, granisetron has a longer half‑life, which can allow for less frequent dosing in certain treatment protocols. Its efficacy in preventing chemotherapy‑induced nausea is comparable, and it may be preferred when a longer duration of action is desired.
What are the storage and handling requirements for Kytril?+
Kytril must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use, and any unused solution should be discarded according to local regulations.
How is Kytril administered?+
Kytril is supplied as a sterile injectable solution for intravenous use. It is typically given as a slow IV push or diluted in compatible IV fluids and administered shortly before the emetogenic stimulus (chemotherapy, radiation, or surgery) under medical supervision.
What are the most serious risks associated with Kytril?+
The most serious adverse reactions include severe allergic responses such as anaphylaxis, cardiac arrhythmias related to QT‑interval prolongation, and rare cases of serotonin syndrome when combined with other serotonergic agents. Patients should be monitored for signs of these conditions during and after administration.
Who should not use Kytril?+
Kytril is contraindicated in individuals with known hypersensitivity to granisetron or any component of the formulation. Caution is advised for patients with a history of prolonged QT interval, severe cardiac disease, or those taking other QT‑prolonging medications; use should be avoided unless the clinical benefit outweighs the risk.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Granisetron
Route
Intravenous Use
Manufacturer
Atnahs Pharma Netherlands B.V.
Origin
EU

Related products

Emegar

Emegar

Granisetron

Stada Arzneimittel Ag
EU
Grandise

Grandise

Granisetron

Lanova Farmaceutici S.R.L.
EU
Granegis

Granegis

Granisetron

Egis Pharmaceuticals Plc
EU
Granegis

Granegis

Granisetron

Egis Pharmaceuticals Plc
EU